CGRP Antibodies as Prophylaxis in Migraine.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30550780.
- Also identified by DOI 10.1016/j.cell.2018.11.049.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Calcitonin Gene-Related Peptide
- Migraine Disorders